AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21741469 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 21741469 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison
Number of subjects: 0
Study 21741469 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacrimation
Number of subjects: 0
Study 19560329 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline n-3 PUFA status
Number of subjects: 0
Study 19560329 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed controls
Number of subjects: 0
Study 16436081 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback-plus (FB+) group
Number of subjects: 0
Study 16436081 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback (FB) group
Number of subjects: 0
Study 16436081 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 14689241 — intervention group
Group type: EXPERIMENTAL
Intervention: Logan's non-invasive graphical analysis
Number of subjects: 0
Study 14689241 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified reference tissue method (SRTM)
Number of subjects: 0
Study 14689241 — intervention group
Group type: EXPERIMENTAL
Intervention: Interindividual averaging
Number of subjects: 0
Study 14689241 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo simulations
Number of subjects: 0
Study 11551575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immune‐enhancing nutritional supplement containing L‐arginine, omega-3 polyunsaturated fatty acids, and yeast RNA (n=25)
Number of subjects: 50
Study 11551575 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) (n=25)
Number of subjects: 50
Study 11551575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immune‐enhancing nutritional supplement (n=25)
Number of subjects: 50
Study 9243688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure ventilation through a laryngeal mask
Number of subjects: 60
Study 9243688 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation through a tracheal tube
Number of subjects: 60
Study 8330828 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 mg glycerol trinitrate (GTN) administered in various forms (2 x 1.2 mg capsules; 6 x 0.4 mg puffs of an atomizer; 2.4 ml of an 0.1% infusion solution)
Number of subjects: 80
Study 8330828 — intervention group
Group type: COMPARATOR
Intervention: 20 mg of butylscopolamine bromide i.v. (BSB)
Number of subjects: 80
Study 6101174 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg daily for two weeks)
Number of subjects: 16
Study 6101174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30250241 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTED
Number of subjects: 12
Study 30250241 — intervention group
Group type: EXPERIMENTAL
Intervention: FED
Number of subjects: 12
Study 24203774 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 391
Study 24203774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 27472478 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with scGOS/lcFOS
Number of subjects: 432
Study 27472478 — intervention group
Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS + 15% FERM
Number of subjects: 432
Study 27472478 — intervention group
Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS + 50% FERM
Number of subjects: 432
Study 27472478 — intervention group
Group type: COMPARATOR
Intervention: 50% fermented formula (50% FERM)
Number of subjects: 432
Study 24395308 — intervention group
Group type: EXPERIMENTAL
Intervention: Low offset femoral group
Number of subjects: 362
Study 24395308 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal offset femoral group
Number of subjects: 362
Study 24395308 — intervention group
Group type: EXPERIMENTAL
Intervention: High offset femoral group
Number of subjects: 362
Study 22275157 — intervention group
Group type: COMPARATOR
Intervention: Actual Amount of Use Test (AAUT) quality of movement (AAUTq)
Number of subjects: 0
Study 22275157 — intervention group
Group type: COMPARATOR
Intervention: Motor Activity Log (MAL) quality of movement (MALq)
Number of subjects: 0
Study 22275157 — intervention group
Group type: COMPARATOR
Intervention: Actual Amount of Use Test (AAUT) amount of use (AAUTa)
Number of subjects: 0
Study 22275157 — intervention group
Group type: COMPARATOR
Intervention: Motor Activity Log (MAL) amount of use (MALa)
Number of subjects: 0
Study 22275157 — intervention group
Group type: COMPARATOR
Intervention: Training-induced spontaneous arm use
Number of subjects: 0
Study 19223520 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release hydrocortisone (MR-HC) 15 mg
Number of subjects: 28
Study 19223520 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release hydrocortisone
Number of subjects: 28
Study 19223520 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling of MR-HC
Number of subjects: 28
Study 17557991 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased portion sizes (50% increase)
Number of subjects: 23
Study 17557991 — intervention group
Group type: COMPARATOR
Intervention: Standard portion sizes
Number of subjects: 23
Study 16827683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-based therapy (n = 33)
Number of subjects: 66
Study 16827683 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine microemulsion-based therapy (n = 33)
Number of subjects: 66
Study 16827683 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 12944209 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 50
Study 10026457 — intervention group
Group type: EXPERIMENTAL
Intervention: Expatriate employees (n = 47)
Number of subjects: 47
Study 10026457 — intervention group
Group type: COMPARATOR
Intervention: Matched non-moving reference group (n = 35)
Number of subjects: 47
Study 8689806 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg buprenorphine
Number of subjects: 8
Study 8689806 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg buprenorphine and 2 mg naloxone combined
Number of subjects: 8
Study 8689806 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg naloxone
Number of subjects: 8
Study 8689806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1660610 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (0.1, 0.25, 0.5, 1.0, 2.0, and 4.0 micrograms)
Number of subjects: 9
Study 1660610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6346939 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia with 0.2% bupivacaine at 0.2 ml/kg.h for 24 hours
Number of subjects: 30
Study 6346939 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptanalgesia with postoperative Piritramid
Number of subjects: 30
Study 31319188 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS) based on 7 variables: age, tumor site, sex, marital status, histological type, tumor size, and surgery.
Number of subjects: 3732
Study 27930408 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 1476
Study 27930408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1476
Study 25792802 — intervention group
Group type: COMPARATOR
Intervention: Transdermal donepezil patch (43.75 mg/12.5 cm², 87.5 mg/25 cm², 175 mg/50 cm²)
Number of subjects: 36
Study 25792802 — intervention group
Group type: COMPARATOR
Intervention: Transdermal donepezil patch
Number of subjects: 36
Study 23506277 — intervention group
Group type: EXPERIMENTAL
Intervention: 127.2 mg lidocaine with 50 μg epinephrine plus 0.5 M mannitol (5 mL formulation)
Number of subjects: 40
Study 23506277 — intervention group
Group type: COMPARATOR
Intervention: 127.2 mg lidocaine with 50 μg epinephrine (3.18 mL formulation)
Number of subjects: 40
Study 23506277 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (lidocaine with and without mannitol)
Number of subjects: 40
Study 21455087 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg) given at 2 doses 8 hrs apart
Number of subjects: 30
Study 21455087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21455087 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg)
Number of subjects: 30
Study 21455087 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and placebo
Number of subjects: 30
Study 19653988 — intervention group
Group type: EXPERIMENTAL
Intervention: STD-14 (0.25 mg/kg/day for 14 days)
Number of subjects: 188
Study 19653988 — intervention group
Group type: EXPERIMENTAL
Intervention: STD-3 (0.25 mg/kg/day for 3 days)
Number of subjects: 188
Study 19653988 — intervention group
Group type: EXPERIMENTAL
Intervention: 71%STD-3 (0.178 mg/kg/day for 3 days)
Number of subjects: 188
Study 19653988 — intervention group
Group type: EXPERIMENTAL
Intervention: 50%STD-3 (0.125 mg/kg/day for 3 days)
Number of subjects: 188
Study 17056362 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 0
Study 17056362 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 0
Study 14652116 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly designed anesthesiology preoperative evaluation form
Number of subjects: 0
Study 10694547 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose total-body irradiation (STBI) - 10 Gy
Number of subjects: 160
Study 10694547 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated total-body irradiation (HTBI) - 14.85 Gy
Number of subjects: 160
Study 9066326 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of propofol/desflurane anesthesia
Number of subjects: 7
Study 9066326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilation from warming and vasoconstriction from cooling
Number of subjects: 7
Study 9066326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature variation (18-26 degrees C)
Number of subjects: 7
Study 9066326 — intervention group
Group type: EXPERIMENTAL
Intervention: Core-to-forehead temperature difference
Number of subjects: 7
Study 9066326 — intervention group
Group type: EXPERIMENTAL
Intervention: Core-to-neck temperature difference
Number of subjects: 7
Study 8259746 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (Group A)
Number of subjects: 22
Study 8259746 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (Group B)
Number of subjects: 22
Study 8259746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (Group C)
Number of subjects: 22
Study 8259746 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 22
Study 3891378 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release furosemide 60 mg daily
Number of subjects: 86
Study 3891378 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release furosemide 30 mg daily
Number of subjects: 86
Study 3891378 — intervention group
Group type: COMPARATOR
Intervention: Bendroflumethiazide 2.5 mg daily
Number of subjects: 86
Study 30091852 — intervention group
Group type: COMPARATOR
Intervention: AG-348 (30-2500 mg single dose)
Number of subjects: 48
Study 30091852 — intervention group
Group type: COMPARATOR
Intervention: AG-348 (15-700 mg every 12 hours or 120 mg every 24 hours for 14 days)
Number of subjects: 48
Study 30091852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29909400 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at bilateral BL32, BL33, and BL35, once a day for the first 4 weeks, then once every other day for the following 4 weeks.
Number of subjects: 16
Study 29909400 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for bowel dysfunction.
Number of subjects: 16
Study 25760277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 45
Study 25760277 — intervention group
Group type: COMPARATOR
Intervention: Otago
Number of subjects: 45
Study 25453528 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniosacral Therapy (CST)
Number of subjects: 50
Study 25453528 — intervention group
Group type: COMPARATOR
Intervention: Light touch sham-control intervention
Number of subjects: 50
Study 22901362 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/d; mean dose = 13.5 mg/d)
Number of subjects: 431
Study 22901362 — intervention group
Group type: COMPARATOR
Intervention: Lithium (300-1,800 mg/d; mean dose = 1,003.3 mg/d)
Number of subjects: 431
Study 20096647 — intervention group
Group type: EXPERIMENTAL
Intervention: II-SG
Number of subjects: 38
Study 20096647 — intervention group
Group type: EXPERIMENTAL
Intervention: II-DSG
Number of subjects: 38
Study 17872488 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube with polyurethane cuff and subglottic secretion drainage (ETT-PUC-SSD)
Number of subjects: 280
Study 17872488 — intervention group
Group type: COMPARATOR
Intervention: Conventional endotracheal tube (ETT-C) with polyvinyl cuff, without subglottic secretion drainage
Number of subjects: 280
Study 17872488 — intervention group
Group type: COMPARATOR
Intervention: ETT-C
Number of subjects: 280
Study 15910516 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin administered at 18:00 or 19:00 hours
Number of subjects: 110
Study 15910516 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at 18:00 or 19:00 hours
Number of subjects: 110
Study 11459433 — intervention group
Group type: EXPERIMENTAL
Intervention: iloprost (0.5‐2 ng/kg/h i.v. infused, 6 h/day)
Number of subjects: 24
Study 11459433 — intervention group
Group type: EXPERIMENTAL
Intervention: supervised physical exercise
Number of subjects: 24
Study 9517367 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of carbamazepine (200-800 mg)
Number of subjects: 60
Study 9517367 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dosing of carbamazepine (400-800 mg twice daily for 14 days)
Number of subjects: 60
Study 8038904 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (600 mg in three divided doses orally)
Number of subjects: 7
Study 8038904 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (10 mg as an iv bolus injection)
Number of subjects: 7
Study 8038904 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone plus sodium valproate
Number of subjects: 7
Study 8038904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3177753 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressive therapy
Number of subjects: 431
Study 3177753 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 431
Study 31012853 — intervention group
Group type: EXPERIMENTAL
Intervention: PFT-guided de-escalation of dual antiplatelet therapy (DAPT)
Number of subjects: 2610
Study 31012853 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with prasugrel for 12 months (control group)
Number of subjects: 2610
Study 31012853 — intervention group
Group type: COMPARATOR
Intervention: Control group (prasugrel)
Number of subjects: 2610
Study 31012853 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided de-escalation group (clopidogrel)
Number of subjects: 2610
Study 28337847 — intervention group
Group type: EXPERIMENTAL
Intervention: BT + EA
Number of subjects: 283
Study 28337847 — intervention group
Group type: EXPERIMENTAL
Intervention: BT
Number of subjects: 283
Study 28337847 — intervention group
Group type: EXPERIMENTAL
Intervention: BT + E
Number of subjects: 283
Study 26416606 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk Well program
Number of subjects: 102
Study 26416606 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 102
Study 23551956 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline mesylate (1 mg) once daily
Number of subjects: 244
Study 23551956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 21962461 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment sessions (GT) of pelvic floor muscle training (PFMT) for 6 weeks, with two 1-hour sessions per week.
Number of subjects: 49
Study 21962461 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment sessions (IT) of pelvic floor muscle training (PFMT) for 6 weeks, with two 1-hour sessions per week.
Number of subjects: 49
Study 21962461 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no treatment during the corresponding time.
Number of subjects: 49
Study 17360209 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized levalbuterol (1.25mg)
Number of subjects: 10
Study 17360209 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (2.5mg)
Number of subjects: 10
Study 17360209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16429430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dead Sea (barometric pressure, 791 +/- 3 mmHg)
Number of subjects: 14
Study 16429430 — intervention group
Group type: COMPARATOR
Intervention: Sea level (barometric pressure, 754 +/- 6 mmHg)
Number of subjects: 14
Study 12624628 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (long half-life)
Number of subjects: 86
Study 12624628 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocoumarol (short half-life)
Number of subjects: 86
Study 12624628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education
Number of subjects: 86
Study 12624628 — intervention group
Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 86
Study 10673512 — intervention group
Group type: EXPERIMENTAL
Intervention: IM862 intranasal drops at a dose of 5 mg, given in two dosing schedules: 5 days on, 5 days off (n = 18)
Number of subjects: 44
Study 10673512 — intervention group
Group type: EXPERIMENTAL
Intervention: IM862 intranasal drops at a dose of 5 mg, given every other day (n = 26)
Number of subjects: 44
Study 10673512 — intervention group
Group type: EXPERIMENTAL
Intervention: IM862 intranasal drops
Number of subjects: 44
Study 8862237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention group
Number of subjects: 228
Study 8862237 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228
Study 1993279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethoglucid (0.565 g, 1% solution) weekly for 6 weeks, then monthly for 1 year
Number of subjects: 77
Study 1993279 — intervention group
Group type: COMPARATOR
Intervention: Keyhole-limpet haemocyanin (KLH) 1 mg subcutaneously, followed by bladder instillations of 30 mg weekly for 6 weeks, then monthly for 1 year
Number of subjects: 77
Study 6394516 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg captopril
Number of subjects: 24
Study 6394516 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg methyldopa
Number of subjects: 24
Study 6394516 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg indapamide
Number of subjects: 24
Study 6394516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29143355 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliances with an occlusal flat table
Number of subjects: 20
Study 29143355 — intervention group
Group type: COMPARATOR
Intervention: Control (no oral-appliance insertion)
Number of subjects: 20
Study 26964901 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/mL ketorolac buccal infiltration
Number of subjects: 40
Study 26964901 — intervention group
Group type: COMPARATOR
Intervention: Normal saline buccal infiltration (control group)
Number of subjects: 40
Study 25823187 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training on a bicycle ergometer for 15 minutes, three times a week at 50-60% of maximal heart rate
Number of subjects: 80
Study 25823187 — intervention group
Group type: COMPARATOR
Intervention: No exercise training (Control)
Number of subjects: 80
Study 22906948 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 94
Study 22906948 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 94
Study 22906948 — intervention group
Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 94
Study 19675960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy plus Motivational Interviewing (CBT + MI)
Number of subjects: 16
Study 19675960 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy plus Psychoeducation (CBT + PE)
Number of subjects: 16
Study 18714219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3‐) ingestion
Number of subjects: 9
Study 18714219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15671428 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK infusion for 24 hours plus usual care (n = 10,091)
Number of subjects: 20201
Study 15671428 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (controls; n = 10,110)
Number of subjects: 20201
Study 12912814 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 64
Study 12912814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 10585975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment (1 mg/kg/day for 9 days followed by 0.5 mg/kg/day for 3 days)
Number of subjects: 40
Study 10585975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 40
Study 10585975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8923547 — intervention group
Group type: EXPERIMENTAL
Intervention: BB (all black)
Number of subjects: 0
Study 8923547 — intervention group
Group type: EXPERIMENTAL
Intervention: MA (matched)
Number of subjects: 0
Study 8923547 — intervention group
Group type: EXPERIMENTAL
Intervention: OPP (opposite)
Number of subjects: 0
Study 8923547 — intervention group
Group type: EXPERIMENTAL
Intervention: BW (one side black, the other white)
Number of subjects: 0
Study 8923547 — intervention group
Group type: EXPERIMENTAL
Intervention: OPP patterns progressively changed into BB patterns
Number of subjects: 0
Study 8923547 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmatched polarity
Number of subjects: 0
Study 1832261 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (8 micrograms.kg‐1 each, two doses with 1 min interval)
Number of subjects: 55
Study 1832261 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate (7 micrograms.kg‐1, single dose)
Number of subjects: 55
Study 1832261 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 55